Circassia logo

CIR - Circassia Share Price

23.75p -0.3  -1.0%

Last Trade - 18/09/20

Small Cap
Market Cap £89.5m
Enterprise Value £168.4m
Revenue £62.4m
Position in Universe 986th / 1807
Unlock CIR Revenue
Relative Strength (%)
1m -21.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 10.8 23.1 46.3 48.3 62.4 62.6 78.3
-25.9 -8.6 +24.0
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Circassia Group PLC revenues increased 29% to £62.4M. Net loss before extraordinary items increased 4% to £48.3M. Revenues reflect operating-NIOX segment increase of 26% to £34.6M, COPD segment increase of 33% to £27.8M, US segment increase of 26% to £38.2M, Asia Pacific segment increase of 53% to £14.5M, Rest of World segment increase from £100K to £300K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CIR
Graphical History


CIR Revenue Unlock CIR Revenue

Net Income

CIR Net Income Unlock CIR Revenue

Normalised EPS

CIR Normalised EPS Unlock CIR Revenue

PE Ratio Range

CIR PE Ratio Range Unlock CIR Revenue

Dividend Yield Range

CIR Dividend Yield Range Unlock CIR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CIR EPS Forecasts Unlock CIR Revenue
Profile Summary

Circassia Group Plc, formerly Circassia Pharmaceuticals Plc, is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company is primarily focused on offering its commercialized asthma management products directly to specialist physicians in various markets. The Company’s NIOX products are used to improve asthma and offers a portfolio of asthma and chronic obstructive pulmonary disease product candidates. The Company’s commercialized chronic obstructive pulmonary disease (COPD) products are Tudorza and Duaklir in the United States. The Company’s pipeline products also include late-stage nitric oxide product LungFit PH, which is a ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated May 19, 2006
Public Since March 13, 2014
No. of Shareholders: n/a
No. of Employees: 322
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share , ,
Exchange London Stock Exchange (AIM)
Shares in Issue 376,982,723
Free Float (0.0%)
Eligible for
CIR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CIR
Upcoming Events for CIR
Frequently Asked Questions for Circassia
What is the Circassia share price?

As of 18/09/20, shares in Circassia are trading at 23.75p, giving the company a market capitalisation of £89.5m. This share price information is delayed by 15 minutes.

How has the Circassia share price performed this year?

Shares in Circassia are currently trading at 23.75p and the price has moved by 32.68% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Circassia price has moved by 58.69% over the past year.

What are the analyst and broker recommendations for Circassia?

Of the analysts with advisory recommendations for Circassia, there are there are currently 0 "buy" , 0 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Circassia is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Circassia next release its financial results?

Circassia is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Circassia dividend yield?

Circassia does not currently pay a dividend.

Does Circassia pay a dividend?

Circassia does not currently pay a dividend.

When does Circassia next pay dividends?

Circassia does not currently pay a dividend.

How do I buy Circassia shares?

To buy shares in Circassia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Circassia?

Shares in Circassia are currently trading at 23.75p, giving the company a market capitalisation of £89.5m.

Where are Circassia shares listed? Where are Circassia shares listed?

Here are the trading details for Circassia:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: CIR
What kind of share is Circassia?

Based on an overall assessment of its quality, value and momentum, Circassia is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Circassia share price forecast 2020?

Shares in Circassia are currently priced at 23.75p. At that level they are trading at 11.58% premium to the analyst consensus target price of 21.29.

Analysts covering Circassia currently have a consensus Earnings Per Share (EPS) forecast of -0.0432 for the next financial year.

How can I tell whether the Circassia share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Circassia. Over the past six months, the relative strength of its shares against the market has been 38.88%. At the current price of 23.75p, shares in Circassia are trading at -1.92% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Circassia PE Ratio?

The Circassia PE ratio based on its reported earnings over the past 12 months is 2.05. The shares are currently trading at 23.75p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Circassia?

Circassia's management team is headed by:

Jo LeCouilliard - NID
Sharon Curran - NID
Jonathan Emms - COO
Ian Johnson - CHM
Garry Watts - NID
Michael Roller - CFO
Who are the major shareholders of Circassia?

Here are the top five shareholders of Circassia based on the size of their shareholding:

Griffiths (Richard) Individual Investor
Percentage owned: 29.69% (111.9m shares)
AstraZeneca PLC Corporation
Percentage owned: 18.85% (71.1m shares)
Harwood Capital LLP Investment Advisor
Percentage owned: 14.87% (56.1m shares)
Invesco Advisers, Inc. Investment Advisor
Percentage owned: 5.8% (21.8m shares)
Lombard Odier Asset Management (Europe) Ltd Investment Advisor
Percentage owned: 4.81% (18.1m shares)
Similar to CIR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.